126454-22-6

126454-22-6 structure

Name: (R)-(+)-Anatabine
Chemical Name: 3-[(2R)-1,2,3,6-tetrahydropyridin-2-yl]pyridine
CAS Number: 126454-22-6
Molecular Formula: C₁₀H₁₂N₂
Molecular Weight: 160.21600
Catalog: Signaling Pathways Membrane Transporter/Ion Channel nAChR
Create Date: 2017-12-30 04:29:05
Modify Date: 2025-08-26 11:49:10
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist[1]. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment[2][3][4].

Name	3-[(2R)-1,2,3,6-tetrahydropyridin-2-yl]pyridine

Description	(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist[1]. Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment[2][3][4].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR Signaling Pathways >> Neuronal Signaling >> nAChR Research Areas >> Inflammation/Immunology Research Areas >> Neurological Disease
References	[1]. Jothi L. Nallasivam, et al. Synthetic modifications of bifunctional homoallylamines: Synthesis of 2-arylpiperidines, (R)-anatabine and (R)-anabasine. An International Journal for Rapid Communication of Synthetic Organic Chemistry. Volume 49, 2019-Issue 21: 2815-2822. [2]. Paris D, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol. 2011 Nov 30;670(2-3):384-91. [3]. Xing H, et al. A Pharmacological Comparison of Two Isomeric Nicotinic Receptor Agonists: The Marine Toxin Isoanatabine and the Tobacco Alkaloid Anatabine. Mar Drugs. 2020 Feb 11;18(2). pii: E106. [4]. eo EJ, et al. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273.